• Erkan Oner, Ilter Demirhan, Meral Miraloglu, Serap Yalin, and KurutasErgul BelgeEBDepartment of Medical Biochemistry, Faculty of Medicine, Sutcu Imam Univestiy, Kahramanmaras, 46090, Türkey..
• Department of Biochemistry, Faculty of Pharmacy, Mersin University, Mersin, 33090, Türkey.
• Afr Health Sci. 2023 Mar 1; 23 (1): 233623-36.

AimsThis paper aimed to investigate the antiviral drugs against Sars-Cov-2 main protease (MPro) using in silico methods.Material And MethodA search was made for antiviral drugs in the PubChem database and antiviral drugs such as Bictegravir, Emtricitabine, Entecavir, Lamivudine, Tenofovir, Favipiravir, Hydroxychloroquine, Lopinavir, Oseltamavir, Remdevisir, Ribavirin, Ritonavir were included in our study. The protein structure of Sars-Cov-2 Mpro (PDB ID: 6LU7) was taken from the Protein Data Bank (www.rcsb. Org) system and included in our study. Molecular docking was performed using AutoDock/Vina, a computational docking program. Protein-ligand interactions were performed with the AutoDock Vina program. 3D visualizations were made with the Discovery Studio 2020 program. N3 inhibitor method was used for our validation.ResultsIn the present study, bictegravir, remdevisir and lopinavir compounds in the Sars-Cov-2 Mpro structure showed higher binding affinity compared to the antiviral compounds N3 inhibitor, according to our molecular insertion results. However, the favipiravir, emtricitabine and lamuvidune compounds were detected very low binding affinity. Other antiviral compounds were found close binding affinity with the N3 inhibitor.ConclusionBictegravir, remdevisir and lopinavir drugs showed very good results compared to the N3 inhibitor. Therefore, they could be inhibitory in the Sars Cov-2 Mpro target.© 2023 Oner E et al.

12 keywords...

hide…